1887
  1. Home
  2. A-Z Publications
  3. Avicenna
  4. Volume 2024, Issue 2
  5. Article
Volume 2024, Issue 2
  • EISSN: 2220-2749

Abstract

COVID-19 is associated with a hypercoagulable state leading to an increased risk of thrombotic events. Although anticoagulation therapy is widely used, the optimal dosing strategy remains uncertain.

The aim of this study was to evaluate the impact of therapeutic versus prophylactic anticoagulation on outcomes in critically ill COVID-19 patients.

A retrospective cohort study was conducted on 315 critically ill COVID-19 patients. Patients were divided into two groups based on their anticoagulation regimen: therapeutic dose and prophylactic dose. The primary outcome was in-hospital mortality, while secondary outcomes included major bleeding events, thromboembolic events, and mechanical ventilation requirements.

No significant difference in mortality was observed between the therapeutic and prophylactic anticoagulation groups. Additionally, there were no significant differences in secondary outcomes.

Our findings suggest that therapeutic anticoagulation may not provide a significant survival benefit compared to prophylactic anticoagulation in critically ill COVID-19 patients. To optimize patient outcomes, a more tailored approach to anticoagulation may be necessary, taking into account individual patient factors and risk assessment. Further prospective studies are needed to definitively establish the optimal anticoagulation strategy, especially in the context of evolving treatment modalities and vaccinations.

© 2024 Author(s), licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/avi.2024.11
2024-12-26
2025-01-10
Loading full text...

Full text loading...

/deliver/fulltext/avi/2024/2/avi.2024.11.html?itemId=/content/journals/10.5339/avi.2024.11&mimeType=html&fmt=ahah

References

  1. Boonyawat K, Chantrathammachart P, Numthavej P, Nanthatanti N, Phusanti S, Phuphuakrat A, et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thromb J. 2020 Nov 2; 18:(1):34. doi: 10.1186/s12959-020-00248-5.
     [Google Scholar]
  2. Gong X, Yuan B, Yuan Y. Incidence and prognostic value of pulmonary embolism in COVID-19: a systematic review and meta-analysis. PLoS One. 2022 Mar 14; 17:(3):e0263580. doi: 10.1371/journal.pone.0263580.
     [Google Scholar]
  3. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 Sep 1; 173:(5):350–361. doi: 110.7326/M20-2566.
     [Google Scholar]
  4. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA – J Am Med Assoc. 2020; 324:(15):1565–1567. doi: 10.1001/jama.2020.17052.
     [Google Scholar]
  5. Voicu S, Ketfi C, Stépanian A, Chousterman BG, Mohamedi N, Siguret V, et al. Pathophysiological processes underlying the high prevalence of deep vein thrombosis in critically Ill COVID-19 patients. Front Physiol. 2021 Jan 8;11:608788. doi: 10.3389/fphys.2020.608788.
     [Google Scholar]
  6. Narasimhan B, Lorente-Ros M, Aguilar-Gallardo JS, Lizardo CP, Narasimhan H, Morton C, et al. Anticoagulation in COVID-19: a review of current literature and guidelines. Hosp Pract (1995). 2021 Dec; 49:(5):307–324. doi: 10.1080/21548331.2021.2007648.
     [Google Scholar]
  7. Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad Med J. 2022 May; 98:(1159):395–402. doi: 10.1136/postgradmedj-2021-139923.
     [Google Scholar]
  8. Muñoz-Rivas N, Abad-Motos A, Mestre-Gómez B, Sierra-Hidalgo F, Cortina-Camarero C, Lorente-Ramos RM, et al. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study. Thromb Res. 2021 Mar;199:132–142. doi: 10.1016/j.thromres.2020.12.024.
     [Google Scholar]
  9. White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, et al. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020 Aug; 50:(2):287–291. doi: 10.1007/s11239-020-02145-0.
     [Google Scholar]
  10. Yasuda H, Mayumi T, Okano H . Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection. 2022 Dec; 50:(6):1453–1463. doi: 10.1007/s15010-022-01809-8.
     [Google Scholar]
  11. Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, et al. Anticoagulation in patients with COVID-19. J Am Coll Cardiol. 2022; 79:(9):917–928. doi: 10.1016/j.jacc.2021.12.023.
     [Google Scholar]
  12. Kow CS, Ramachandram DS, Hasan SS. The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother. 2022 Feb; 28:(2):257–265. doi: 10.1016/j.jiac.2021.11.008.
     [Google Scholar]
  13. Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, et al. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Hear J – Cardiovasc Pharmacother. 2022 Sep 29; 8:(7):677–686. doi: 10.1093/ehjcvp/pvab070.
     [Google Scholar]
  14. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339.
     [Google Scholar]
  15. Gordon AJ, Govindarajan P, Bennett CL, Matheson L, Kohn MA, Camargo C, et al. External validation of the 4C Mortality Score for hospitalised patients with COVID-19 in the RECOVER network. BMJ Open. 2022 Apr 21; 12:(4):e054700. doi: 10.1136/bmjopen-2021-054700.
     [Google Scholar]
  16. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2020 Aug 4; 76:(5):594–622. doi: 10.1016/j.jacc.2020.04.053.
     [Google Scholar]
  17. Manrique S, Claverias L, Magret M, Masclans JR, Bodi M, Trefler S, et al. Timing of intubation and ICU mortality in COVID-19 patients: a retrospective analysis of 4198 critically ill patients during the first and second waves. BMC Anesthesiol. 2023 Apr 27; 23:(1):140. doi: 10.1186/s12871-023-02081-5.
     [Google Scholar]
  18. Afshar ZM, Pirzaman AT, Hosseinzadeh R, Babazadeh A, Moghadam MAT, Miri SR, Sio TT, et al. Anticoagulant therapy in COVID-19: a narrative review. Clin Transl Sci. 2023 Sep; 16:(9):1510–1525. doi: 10.1111/cts.13569.
     [Google Scholar]
  19. Vio R, Giordani AS, Stefil M, Alturki A, Russo V, China P, et al. Therapeutic vs. prophylactic anticoagulation in Covid-19 patients: a systematic review and meta-analysis of real-world studies. Minerva Cardiol Angiol. 2022 Dec; 70:(6):652–662. doi: 10.23736/S2724-5683.22.06230-5.
     [Google Scholar]
  20. Kattakola Y, Prasad R, Sharma R, Wanjari MB. High-dose prophylactic anticoagulation for COVID-19 Pneumonia: a review of benefits and risks. Cureus. 2023 Apr 17; 15:(4):e37705. doi: 10.7759/cureus.37705.
     [Google Scholar]
  21. Gabara C, Solarat B, Castro P, Fernández S, Badia JR, Toapanta D, et al. Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients [Estrategias de anticoagulación y riesgo de sangrado en pacientes ingresados en una Unidad de Cuidados Intensivos por COVID-19]. Med Intensiva. 2023 Jan; 47:(1):1–8. doi: 10.1016/j.medin.2021.07.004.
     [Google Scholar]
  22. Rachina S, Belkova Y, Shchendrygina A, Suvorov A, Bourgeois D, Karuk M, et al. Safety and efficacy of different anticoagulant doses for patients with COVID-19 in the ICU: a systematic review and meta-analysis. J Clin Med. 2023 Mar 13; 12:(6):2222. doi: 10.3390/jcm12062222.
     [Google Scholar]
  23. Rahi MS, Parekh J, Pednekar P, Mudgal M, Jindal V, Gunasekaran K. Role of therapeutic anticoagulation in COVID-19: the current situation. Hematol Rep. 2023 Jun 5; 15:(2):358–369. doi: 10.3390/hematolrep15020037.
     [Google Scholar]
  24. de Matos Aquino B, Paludeto GT, Neto AC, Bignardi PR. Anticoagulation therapy in hospitalized patients with COVID-19: a meta-analysis of randomized clinical trials. Bratisl Lek Listy. 2023; 124:(11):848–855. doi: 10.4149/BLL_2023_131.
     [Google Scholar]
  25. Scheier TC, Carlin S, Wills NK, Wasserman S, Mertz D, Eikelboom JW. Efficacy and safety of intensified vs standard prophylactic anticoagulation therapy in patients hospitalized with Coronavirus Disease 2019: updated systematic review and meta-analysis. Open Forum Infect Dis. 2023 Oct 10; 10:(11):ofad506. doi: 10.1093/ofid/ofad506.
     [Google Scholar]
  26. Patel NG, Bhasin A, Feinglass JM, Angarone MP, Cohen ER, Barsuk JH. Mortality, critical illness, and mechanical ventilation among hospitalized patients with COVID-19 on therapeutic anticoagulants. Thromb Update. 2021;2:100027. doi: 10.1016/j.tru.2020.100027.
     [Google Scholar]
  27. Rauch-Kröhnert U, Puccini M, Placzek M, Beyer-Westendorf J, Jakobs K, Friebel J, et al. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. Clin Res Cardiol. 2023 Nov; 112:(11):1620–1638. doi: 10.1007/s00392-023-02240-1.
     [Google Scholar]
  28. Talasaz AH, Sadeghipour P, Mehdizadeh K, Rad NK, Bikdeli B, Lip GYH, et al. Knowledge gaps for prophylactic use of antithrombotic agents in patients with COVID-19: insights into new SARS-CoV-2 variants, vaccination status, and emerging oral antivirals. Thromb Haemost. 2023 Feb; 123:(2):186–191. doi: 10.1055/a-1956-9641.
     [Google Scholar]
/content/journals/10.5339/avi.2024.11
Loading
Anticoagulation strategies and clinical outcomes in critically ill SARS-CoV-2 patients: A retrospective cohort study
Avicenna 2024, 11 (2024); https://doi.org/10.5339/avi.2024.11
/content/journals/10.5339/avi.2024.11
/content/journals/10.5339/avi.2024.11
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): anticoagulation, bleeding, COVID-19, mortality and thromboembolic events

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error